Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination
NCT ID: NCT04706390
Last Updated: 2024-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2500 participants
OBSERVATIONAL
2021-01-12
2030-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
NCT04892797
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
NCT04381819
Evaluating the Immune Response for COVID-19
NCT04348422
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
NCT04779359
Mechanisms for Covid-19 Disease Complications
NCT04314232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To compare immune responses after natural SARS-CoV-2 infection and COVID-19 vaccination The secondary aims are
* To compare the duration and breadth of antibody responses between natural infection and vaccination.
* To investigate the duration and breadth of B and T cellular responses between natural infection and vaccination.
* To evaluate the short and long term complications after natural infection and vaccination.
* To find out if previous infection skews the immune response after vaccination.
* To study reinfection after natural infection and vaccination.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health care workers
500-1000 health care workers prioritized for early vaccination
covid-19 vaccine
vaccination
prioritized patient populations
2000 individuals in patient populations prioritized for vaccinations
covid-19 vaccine
vaccination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
covid-19 vaccine
vaccination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* unable or unwilling to provide informed consent
20 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Haukeland University Hospital
OTHER
University of Bergen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rebecca Cox
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rebecca J Cox, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Bergen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bergen
Bergen, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cox RJ, Brokstad KA, Krammer F, Langeland N; Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Lancet Infect Dis. 2021 Feb;21(2):168. doi: 10.1016/S1473-3099(20)30466-7. Epub 2020 Jun 15. No abstract available.
Trieu MC, Bansal A, Madsen A, Zhou F, Saevik M, Vahokoski J, Brokstad KA, Krammer F, Tondel C, Mohn KGI, Blomberg B, Langeland N, Cox RJ; Bergen COVID-19 Research Group. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737.
Bredholt G, Saevik M, Soyland H, Ueland T, Zhou F, Pathirana R, Madsen A, Vahokoski J, Lartey S, Halvorsen BE, Dahl TB, Trieu MC, Mohn KG, Brokstad KA, Aukrust P, Tondel C, Langeland N, Blomberg B, Cox RJ; Bergen COVID-19 Research Group. Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. Vaccine X. 2024 Sep 25;20:100564. doi: 10.1016/j.jvacx.2024.100564. eCollection 2024 Oct.
Hansen L, Brokstad KA, Bansal A, Zhou F, Bredholt G, Onyango TB, Sandnes HH, Elyanow R, Madsen A, Trieu MC, Saevik M, Soyland H, Olofsson JS, Vahokoski J, Ertesvag NU, Fjelltveit EB, Shafiani S, Tondel C, Chapman H, Kaplan I, Mohn KGI, Langeland N, Cox RJ. Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine X. 2023 Apr;13:100262. doi: 10.1016/j.jvacx.2023.100262. Epub 2023 Jan 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID-19vacc-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.